Original Articles
Copyright ©The Author(s) 1998. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 1998; 4(5): 404-408
Published online Oct 15, 1998. doi: 10.3748/wjg.v4.i5.404
Immuno-protective effect of tumor cell vaccine on Kunming mice bearing Ehrlich ascites tumor
Zheng Ma, Shao-Juan Zhou, Kai-Chun Wu, Bo-Rong Pan, Tai-Dong Qiao, Bao-Jun Chen, Dai-Ming Fan
Zheng Ma, Shao-Juan Zhou, Kai-Chun Wu, Bo-Rong Pan, Tai-Dong Qiao, Bao-Jun Chen, Dai-Ming Fan, Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi’an 710033, Shaanxi Province, China
Zheng Ma, female, born on 1970-23-06 in Xi’an, Shaanxi Province, graduated from Department of Medicine, the Fourth Military Medical University (FMMU) with Bachelor of Medicine in 1994, and as and a postgraduate from Institute of Digestive Diseases, the FMMU with Master of Medicine in 1997, now a Ph.D. student.
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Dai-Ming Fan Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi’an 710033, Shaanxi Province, China
Telephone: +86-29-2539041 Fax.+86-29-2539041
Received: May 20, 1998
Revised: August 19, 1998
Accepted: September 12, 1998
Published online: October 15, 1998
Abstract

AIM: To evaluate the immunity of chemically modified tumor cell vaccine.

METHODS: Tumor cell vaccines (TCV) were prepared by incubating the live Ehrlich ascites tumor cells with concanavalin A-mitomycin C (ConA-MMC), mitomycin C (MMC), concanavalin A-glutaraldehyde (ConA-Glu), glutaraldehyde ( Glu ), or paraformaldehyde ( Para ), respectively. The whole cell or soluble forms of the vaccines were administered intraperitoneally into Kunming mice once a week for three times prior to the intraperitoneal inoculation of a lethal dose of live tumor cells. A second challenge with live tumor cells was given four weeks later. Survival and antibody production of the mice were analyzed.

RESULTS: After the first challenge, the mice, received whole TCV of ConA-MMC, MMC (P < 0.01) and Glu (P < 0.05) promoted survival incidence than the controls. All the treated mice had the survival time prolonged. ConA-MMC vaccine treated mice had longer survival days than that of ConA-Glu ones (P < 0.05). For the soluble TCV immunized mice, those treated with vaccines of Para (P < 0.01), ConA-Para and ConA-Glu (P < 0.05) had longer survival periods compared with that of the controls. Following the second challenge, survival incidence of the mice received vaccines of ConA-MMC, MMC, ConA-Glu or Glu was significantly increased (P < 0.01). Moreover, all the treated mice had the survival time prolonged, and ConA-MMC vaccine treated mice had longer survival days than that of Para treated ones (P < 0.05). Antibodies against Ehrlich ascites tumor cells were found to be positive in sera of the mice treated with whole TCV of ConA-MMC.

CONCLUSION: Ehrlich ascites tumor cells are immunogenic when treated with ConA-MMC, MMC, ConA-Glu, Glu or Para, which might act as safe and effective tumor vaccines with safety and effectiveness.

Keywords: Ehrlich ascites tumor; tumor cell vaccine; kunming mice; antigen, neoplasm